New Breakthrough Drug Sotatracept Brings Hope to Patients with Pulmonary Embolism

Groundbreaking Medical Discovery: Promising News for Countless Patients across the Globe

Pulmonary embolism is a serious condition that primarily affects young people, especially women. The disease can occur at any age, but the peak incidence occurs between the ages of 30-40. Patients are categorized based on function levels and risk levels ranging from 1 (highest) to 4 (lowest).

After a decade of no advancements in the treatment of pulmonary embolism, the American Food and Drug Administration (FDA) has approved sotatracept as the first drug in the world to treat the disease itself. This breakthrough drug offers patients improvements beyond existing treatments, improving survival rates, delaying disease progression, and reducing the risk of worsening disease or death by approximately 84%.

The Ministry of Health typically approves drugs that have passed FDA approval after receiving research findings from the company. Sotatracept has a unique mechanism of action that inhibits the component “activin,” changing the mechanism of cells driving the disease. This new drug brings significant advancements to patients who have not found balance with existing treatments.

Pulmonary hypertension is a serious condition with a significant risk to life. Prof. Mordechai Kramer, director of the pulmonary department at Blinson Hospital, says that sotatracept brings hope to patients who have been struggling with this debilitating disease for years.”

Leave a Reply